Lucid DiagnosticsLUCD
LUCD
About: Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Employees: 70
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
40% more capital invested
Capital invested by funds: $2M [Q3] → $2.8M (+$805K) [Q4]
14% more funds holding
Funds holding: 28 [Q3] → 32 (+4) [Q4]
1.04% more ownership
Funds ownership: 4.54% [Q3] → 5.58% (+1.04%) [Q4]
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$3
100%
upside
Avg. target
$3
100%
upside
High target
$3
100%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Needham Mike Matson 47% 1-year accuracy 58 / 124 met price target | 100%upside $3 | Buy Maintained | 24 Mar 2025 |
Financial journalist opinion
Based on 11 articles about LUCD published over the past 30 days
Neutral
Seeking Alpha
6 hours ago
Lucid Diagnostics Inc. (LUCD) Q4 2024 Earnings Call Transcript
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q4 2024 Earnings Conference Call March 24, 2025 8:30 AM ET Company Participants Matt Riley - Senior Director, Investor Relations Lishan Aklog - Chairman & Chief Executive Officer Dennis McGrath - Chief Financial Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Mark Massaro - BTIG Mike Matson - Needham & Company Anthony Vendetti - Maxim Group Ed Woo - Ascendiant Capital Operator Good morning, and welcome to the Lucid Diagnostics Fourth Quarter 2024 Business Update Conference Call. At this time, all lines are in listen-only mode.
Negative
Zacks Investment Research
8 hours ago
Lucid Diagnostics Inc. (LUCD) Reports Q4 Loss, Lags Revenue Estimates
Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.23 per share a year ago.
Neutral
PRNewsWire
11 hours ago
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Processed a record 4,042 EsoGuard tests in 4Q24, a 45% sequential and 84% annual increase Recognized EsoGuard revenue of $1.2 million in 4Q24 New sales channel generated over 20 new cash-pay concierge medicine contracts Secured first agreement to pay for EsoGuard under state biomarker legislation Conference call and webcast to be held today, March 24 th at 8:30 AM EDT NEW YORK , March 24, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today provided a business update for the Company and reported financial results for the fourth quarter and full year ended December 31, 2024. Conference Call and Webcast The webcast will take place on Monday, March 24, 2024, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com.
Neutral
PRNewsWire
4 days ago
Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening
Highlights society guidelines recommending non-endoscopic biomarker testing, such as Lucid's EsoGuard Esophageal DNA Test, as an acceptable alternative to endoscopy NEW YORK , March 20, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that a recent update to the National Comprehensive Cancer Network ® (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) focused on Esophageal and Esophagogastric Junction Cancers (Version 1.2025) has added a new section on esophageal precancer (Barrett's Esophagus or BE) screening. The NCCN Guidelines® now reference professional society guidelines on BE screening, including the most recent American College of Gastroenterology (ACG) Clinical Guideline which recommends non-endoscopic biomarker testing, such as Lucid's EsoGuard® Esophageal DNA Test performed on samples collected with its EsoCheck® Esophageal Cell Collection Device, as an acceptable alternative to invasive upper endoscopy to detect esophageal precancer.
Neutral
PRNewsWire
6 days ago
Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
Study confirms clinical utility of EsoGuard as a non-invasive triage tool to significantly increase positive yield of invasive upper endoscopy NEW YORK , March 18, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that its ENVET-BE clinical utility study has been accepted for publication in Gastroenterology & Hepatology —the fifth peer-reviewed publication of clinical utility data for Lucid's EsoGuard® Esophageal DNA Test, and the second to present findings from a real-world screening population. The manuscript, entitled Enhancing the Diagnostic Yield of EGD for Diagnosis of Barrett's Esophagus Through Methylated DNA Biomarker Triage , demonstrates that confirmatory upper endoscopy (EGD) performed in EsoGuard-positive patients had a substantially higher diagnostic yield for detecting esophageal precancer (Barrett's Esophagus or BE) than the expected yield of screening EGD alone in at-risk patients.
Neutral
PRNewsWire
1 week ago
Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test
Regional Blue Cross Blue Shield plan will cover non-invasive screening of esophageal precancer and cancer NEW YORK , March 13, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that Highmark Blue Cross Blue Shield, an independent licensee of the Blue Cross and Blue Shield Association, has issued a positive coverage policy for non-invasive screening of esophageal precancer and cancer in New York state. The new policy will cover Lucid's EsoGuard® Esophageal DNA Test in patients who meet established criteria for esophageal precancer testing consistent with professional society guidelines.
Neutral
PRNewsWire
2 weeks ago
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , March 10, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Monday, March 24, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D.
Neutral
PRNewsWire
2 weeks ago
Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering
NEW YORK , March 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced registered direct offering of 13,939,331 shares of common stock at a purchase price of $1.10 per share. The gross proceeds to the Company from this offering are approximately $15.3 million, before deducting the approximately $0.8 million in placement agent's fees and other offering expenses payable by the Company.
Neutral
PRNewsWire
2 weeks ago
Lucid Diagnostics Announces $15.3 Million Registered Direct Offering
NEW YORK , March 4, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it has entered into subscription agreements with certain accredited investors to sell 13,939,331 shares of common stock at a purchase price of $1.10 per share in a registered direct offering. The gross proceeds to the Company from this offering are expected to be approximately $15.3 million, before deducting the approximately $0.8 million in placement agent's fees and other offering expenses payable by the Company.
Neutral
PRNewsWire
3 weeks ago
Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD
Lucid to support study of this expanded indication for esophageal precancer testing in partnership with NIH investigators NEW YORK , Feb. 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that a consortium of prestigious academic medical centers, led by principal investigators from Case Western Reserve University (CWRU) and University Hospitals (UH), has been awarded an $8 million National Institutes of Health (NIH) R01 grant to conduct a five-year clinical study designed to evaluate esophageal precancer detection using Lucid's EsoCheck® Esophageal Cell Collection Device and EsoGuard® Esophageal DNA Test among at-risk individuals without symptoms of chronic gastroesophageal reflux disease (GERD). The study, "A Clinical Trial of Cancer Prevention by Biomarker Based Detections of Barrett's Esophagus and Its Progression," aims to evaluate the effectiveness of EsoCheck and EsoGuard in detecting esophageal precancer (Barrett's Esophagus or BE) to prevent esophageal cancer (EAC) within a non-GERD at-risk population.
Charts implemented using Lightweight Charts™